Fiocruz Amazônia is developing a vaccine against malaria

Brazil is developing a vaccine against malaria, a disease that last year reached 145,000 people in the country alone, 99 percent of them in the states of the Amazon. Symptoms include high fever, chills, tremors, sweating, and headache.

The study of the ILMD – Instituto Leônidas & Maria Deane in Fiocruz Amazônia is being carried out in collaboration with the Fundação de Medicina Tropical.

Because malaria is transmitted from the bite of a mosquito infected by a protozoan, laboratory experiments seek to neutralize this protozoan insect in the organism.

Brazilian research coordinator Stéfanie Lopes commented that the disease could recur even without a new bite from an infectious insect if the treatment is not done properly.

Another reason for developing a malaria vaccine is the replacement of existing drugs today treatment. According to researcher Stéfanie Lopes, these drugs cannot be prescribed to anyone and should not be used for long periods of time because they cause serious side effects.

The Brazilian research coordinator explains that a vaccine against malaria is already being tested in African countries, but it is fighting another type of protozoan. The vaccine project developed here in the country is supported by the Japanese Global Fund for Innovative Technology in Health. And yet, the participation of four Japanese universities and the University of Cambridge in the UK.

Leave a Comment